Melphalan, 5-Fluorouracil, and Medroxyprogesterone Acetate in Metastatic Endometrial Carcinoma
- 31 January 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 67 (2), 261-264
- https://doi.org/10.1097/00006250-198602000-00019
Abstract
Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy. The objective response rate was 48%, and 20% complete responses. The estimated median progression-free survival time was only five months (0.5 to 65 months) with estimated two- and five-year progression-free survival rates of 16 and 13%, respectively. The estimated median progression-free survival time was 24 months for complete responders; the progression-free survival times were significantly longer than the survival times (median = four months) for all other patietns (P = .0002). Whether or not the addition of cytotoxic chemotherapy to progesterone hormonal therapy for metastatic endometrial carcinoma lengthens survival time is still open to question.This publication has 5 references indexed in Scilit:
- MULTIDRUG TREATMENT OF ADVANCED AND RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY1984
- Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimensCancer, 1982
- Medroxyprogesterone acetate (depo-provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinomaCancer, 1980
- MELPHALAN, 5-FLUOROURACIL, AND MEDROXYPROGESTERONE ACETATE IN METASTATIC OR RECURRENT ENDOMETRIAL CARCINOMA - PRELIMINARY-REPORT1980
- TREATMENT OF ADVANCED ADENOCARCINOMA OF ENDOMETRIUM WITH MELPHALAN, 5-FLUOROURACIL, AND MEDROXYPROGESTERONE ACETATE - PRELIMINARY-STUDY1977